Keybanc Maintains Overweight on Monday.Com, Lowers Price Target to $270

Keybanc analyst Jackson Ader maintains Monday.Com (NASDAQ:MNDY) with a Overweight and lowers the price target from $280 to $270.

Benzinga19:02

Teva Focus of FTC Investigation Over Inhaler Patents

Seeking AlphaJul 1 22:22

Snowflake, Fox, Global-E Online Added to America's Conviction List: Goldman

Seeking AlphaJul 1 20:57

Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes

4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in HelsinkiNew sub-analysis of PEARL data highlights potential neg

BenzingaJun 28 23:31

'The U.S. Readies to Evacuate Americans From Lebanon If Fighting Between Israel and Hezbollah Intensifies' - NBC News

'The U.S. Readies to Evacuate Americans From Lebanon If Fighting Between Israel and Hezbollah Intensifies' - NBC News

BenzingaJun 28 04:28

Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23

Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $19 to $23.

BenzingaJun 27 23:37